Authored By: Sarah
11 Jul 2024

 Castration-Resistant Prostate Cancer (CRPC) Treatment Market to grow by USD 5.98 billion between 2024-2028

According to a research report “ Castration-Resistant Prostate Cancer (CRPC) Treatment Market” by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Therapy (Hormonal therapy, Chemotherapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 5.98 billion at a CAGR of  8.83% during the forecast period. The global burden of cancer continues to rise, with over ten million annual deaths, making it the leading cause. Among these, prostate cancer is a significant contributor, causing over a million deaths each year. The exact cause of prostate cancer remains elusive, but age and other risk factors increase the likelihood of its development. With the aging population projected to double from 12% to 22% between 2015 and 2050, the incidence of castration-resistant prostate cancer (CRPC) is expected to rise, creating a substantial market opportunity for innovative treatment solutions..

Browse market data tables, figures, and in-depth TOC on “Castration-Resistant Prostate Cancer (CRPC) Treatment Market” by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Therapy (Hormonal therapy, Chemotherapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Distribution Channel, the Hospital pharmacies segment is projected to dominate the market size in 2024.

In the CRPC treatment market, hormonal therapy held the largest market share in 2023. This segment's growth can be attributed to its ability to inhibit testosterone production or delivery to cancer cells in the prostate, thereby impeding their growth. Hormonal therapy's significance lies in its application for metastatic prostate cancer, where cancer has spread to other organs, making it a crucial intervention in managing this advanced stage of the disease. By disrupting the cancer cells' dependence on testosterone, hormonal therapy induces cell death or slows down their growth, making it a vital component in the global CRPC treatment landscape.

By Therapy, Hormonal therapy  segment is expected to hold the largest market size for the year 2024.

In the CRPC treatment market, hospital pharmacies secured the leading market share in 2023 due to their strategic role within healthcare facilities. Hospital pharmacies are dedicated to managing medication prescriptions and distribution, encompassing tasks from selection and procurement to administration and review. Adherence to patient safety principles is paramount, ensuring accurate dosages, administration routes, timing, drug information, and documentation for all prescribed medications.

North America is forecasted to hold the largest market size by region in 2024.

The North American CRPC treatment market is experiencing robust growth due to the escalating prevalence of prostate cancer cases and the region's sophisticated healthcare infrastructure. In 2022, US healthcare spending surged past USD4.5 trillion, representing a 3% increase over the previous year. This significant financial investment in healthcare is driving demand for advanced CRPC therapies. Furthermore, the increasing number of prostate cancer patients in North America presents lucrative opportunities for market participants.

The Castration-Resistant Prostate Cancer (CRPC) Treatment Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Active Biotech AB
  • Allarity Therapeutics Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • BeiGene Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Everest Pharmaceuticals Ltd.
  • F. Hoffmann La Roche Ltd.
  • Johnson and Johnson
  • Medias Klinikum GmbH and Co. KG
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Robotic Prostate Centre Cambridge
  • Sanofi SA
  • The Focal Therapy Clinic
  • Ono Pharmaceutical Co. Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

In the realm of oncology, the Castration-Resistant Prostate Cancer (CRPC) treatment market represents a significant and growing sector. With an aging population comes an increased incidence of prostate ailments, including CRPC. Symptoms such as shortness of breath, weight loss, and difficulty urinating are common in CRPC patients. Traditional treatments for CRPC include testosterone-lowering therapies like medical and surgical castration, hormone therapy, and combination therapies. Regulatory agencies continue to approve new treatments, such as abiraterone and enzalutamide, which are targeted therapies that inhibit the production of testosterone. New treatments, including radiotherapy and personalized medicine, are also under investigation. The diagnosis and management of CRPC require a multidisciplinary approach, and the use of conventional medications and new treatments continues to evolve.

Market Research Overview

In the context of healthcare expenditure, the geriatric population faces a significant challenge with the incidence of Castration-Resistant Prostate Cancer (CRPC). CRPC is a serious ailment characterized by testosterone-lowering therapy resistance, leading to symptoms such as shortness of breath, weight loss, and difficulty urinating. Various treatment options are available, including conventional medications like corticosteroids, non-steroidal antiandrogens, antineoplastic agents, and targeted therapies such as abiraterone acetate and enzalutamide. These treatments can be administered through different distribution channels, including online pharmacies, retail pharmacies, and hospital pharmacies. The CRPC treatment market is vast and complex, with various mechanisms of resistance and efficacy considerations. Regulatory agencies oversee the development and approval of new treatments, including mechanisms like microtubule inhibitors, androgen receptor inhibitors, and targeted therapies like radiotherapy, immunotherapy, chemotherapy, and second-line hormone therapy. Technological integration, such as liquid biopsies, genomic testing, and imaging technologies, plays a crucial role in diagnosis and personalized medicine approaches. The European market is a significant player in this space, with ongoing clinical trials exploring the potential of combination therapies and innovative drug delivery methods like the oral route and injectable route.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio